CDK1 and colonic neoplasm: Higher doses of silybin reduce cdc2/p34 kinase activity, decrease the protein expression of cdc25C, cdc2/p34, and cyclin B1, and block HT-29 colon cancer cells in the G2 phase (Graves et al., 2000).